Challenges persist, as the clinical research sector can be slow to adopt these innovations. Comprehensive evidence and ...
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...
Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...
Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.
Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...
Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...